Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AdJane Biosciences is a clinical-stage vaccine platform company based in Delft, Netherlands, developing next-generation intranasal and intramuscular vaccines. The company's proprietary native Outer Membrane Vesicle (nOMV) platform, derived from Neisseria meningitidis, is designed to close the mucosal immunity gap by inducing both systemic and mucosal immune responses. AdJane's modular plug-and-play technology enables the rapid incorporation of multiple antigens to target pandemic preparedness, antimicrobial resistance, and global infectious disease challenges. The platform has been clinically validated in a Phase 1 trial, demonstrating safety, tolerability, and mucosal immunogenicity in humans.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on AdJane Biosciences.